Agilent Technologies, Inc.
A
Laboratory Analytical Instruments
Mkt Cap
$43.34BPE
35.07Debt
$2.555BCash
$1.75BEV
$44.15BFCF
$1.649BP/E Ratio
35.07Debt
$2.555BCash
$1.75BEV
$44.15BFCF
$1.649BCharts data: {"Earnings":[{"time":"2014-10-30","value":504000000},{"time":"2015-10-30","value":401000000},{"time":"2016-10-30","value":462000000},{"time":"2017-10-30","value":684000000},{"time":"2018-10-30","value":316000000},{"time":"2019-10-30","value":1071000000},{"time":"2020-10-30","value":719000000},{"time":"2021-10-30","value":1210000000},{"time":"2022-10-30","value":1254000000},{"time":"2023-10-30","value":1240000000}],"Sales":[{"time":"2014-10-30","value":4048000000},{"time":"2015-10-30","value":4038000000},{"time":"2016-10-30","value":4202000000},{"time":"2017-10-30","value":4472000000},{"time":"2018-10-30","value":4914000000},{"time":"2019-10-30","value":5163000000},{"time":"2020-10-30","value":5339000000},{"time":"2021-10-30","value":6319000000},{"time":"2022-10-30","value":6848000000},{"time":"2023-10-30","value":6833000000}],"Net Margins":[{"time":"2014-10-30","value":0.12450592885375494},{"time":"2015-10-30","value":0.0993065874195146},{"time":"2016-10-30","value":0.1099476439790576},{"time":"2017-10-30","value":0.15295169946332737},{"time":"2018-10-30","value":0.06430606430606431},{"time":"2019-10-30","value":0.2074375363160953},{"time":"2020-10-30","value":0.13466941374789287},{"time":"2021-10-30","value":0.1914859946194018},{"time":"2022-10-30","value":0.18311915887850466},{"time":"2023-10-30","value":0.18147226693985072}],"Assets":[{"time":"2014-10-30","value":10831000000},{"time":"2015-10-30","value":7479000000},{"time":"2016-10-30","value":7802000000},{"time":"2017-10-30","value":8426000000},{"time":"2018-10-30","value":8541000000},{"time":"2019-10-30","value":9452000000},{"time":"2020-10-30","value":9627000000},{"time":"2021-10-30","value":10705000000},{"time":"2022-10-30","value":10532000000},{"time":"2023-10-30","value":10763000000}],"Stockholders Equity":[{"time":"2014-10-30","value":5301000000},{"time":"2015-10-30","value":4170000000},{"time":"2016-10-30","value":4246000000},{"time":"2017-10-30","value":4835000000},{"time":"2018-10-30","value":4571000000},{"time":"2019-10-30","value":4748000000},{"time":"2020-10-30","value":4873000000},{"time":"2021-10-30","value":5389000000},{"time":"2022-10-30","value":5305000000},{"time":"2023-10-30","value":5845000000}],"ROE":[{"time":"2014-10-30","value":0.09507640067911714},{"time":"2015-10-30","value":0.0961630695443645},{"time":"2016-10-30","value":0.10880829015544041},{"time":"2017-10-30","value":0.14146845915201656},{"time":"2018-10-30","value":0.0691314810763509},{"time":"2019-10-30","value":0.22556866048862678},{"time":"2020-10-30","value":0.14754771188179766},{"time":"2021-10-30","value":0.22453145295973279},{"time":"2022-10-30","value":0.23638077285579642},{"time":"2023-10-30","value":0.21214713430282292}],"ROA":[{"time":"2014-10-30","value":0.12205705844335703},{"time":"2015-10-30","value":0.1025538173552614},{"time":"2016-10-30","value":0.11009997436554729},{"time":"2017-10-30","value":0.11559458817944458},{"time":"2018-10-30","value":0.11954103734925653},{"time":"2019-10-30","value":0.10505713076597545},{"time":"2020-10-30","value":0.09556455801391918},{"time":"2021-10-30","value":0.12704343764595982},{"time":"2022-10-30","value":0.15362704139764527},{"time":"2023-10-30","value":0.1254297129053238}]}
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
DCF
Discounted Cash Flow Valuation of Agilent Technologies, Inc.
Value
Growth
%
%
Discount
%
%
Multiple
| g\r | +10% | +11% | +12% | +13% | +14% |
|---|---|---|---|---|---|
| 0% | 10 | 9 | 8 | 8 | 7 |
| +1% | 11 | 10 | 9 | 8 | 8 |
| +2% | 13 | 11 | 10 | 9 | 8 |
| +3% | 14 | 13 | 11 | 10 | 9 |
| +4% | 17 | 14 | 12 | 11 | 10 |
| Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF | $1.649B | $1.869B | $2.1B | $2.341B | $2.588B | $2.837B | $3.084B | $3.324B | $3.551B | $3.762B | $3.95B | $39.5B |
| DCF | $1.625B | $1.588B | $1.539B | $1.48B | $1.411B | $1.333B | $1.25B | $1.161B | $1.069B | $976.3M | $9.763B | |
| Value | $23.2B | |||||||||||
In the chart Earnings are multiplied by this value.
Earnings Growth 18%
Earnings Stability 60%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 10-2015 | 10-2016 | 10-2017 | 10-2018 | 10-2019 | 10-2020 | 10-2021 | 10-2022 | 10-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.9% | 11% | 15% | 6.4% | 21% | 13% | 19% | 18% | 18% | 18% |
| ROA | 10% | 11% | 12% | 12% | 11% | 9.6% | 13% | 15% | 13% | 12% |
| ROE | 9.6% | 11% | 14% | 6.9% | 23% | 15% | 22% | 24% | 21% | 20% |
What is the average Net Margin?
The average Net Margin over the past 5 years is +16.04%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is +1.63%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is +12.1%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is +0.59%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is +18.59%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is +2.36%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 10-2015 | 10-2016 | 10-2017 | 10-2018 | 10-2019 | 10-2020 | 10-2021 | 10-2022 | 10-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | 4.21 | 2.92 | 2.82 | 1.98 | 2.78 | 2.94 | 2.10 | 2.71 | 1.86 | 1.55 |
| Debt Equity | 0.40 | 0.45 | 0.42 | 0.39 | 0.51 | 0.48 | 0.51 | 0.52 | 0.47 | 0.41 |
| MIN | ||||||||||
| Graham Stability | - | - | 100% | 61% | 100% | 100% | 100% | 100% | 100% | 61% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is 1.55.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -0.05.
What is the Graham’s Stability?
Graham’s Stability measure stands at 0.61.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 10-2016 | 10-2018 | 10-2020 | 10-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 7.2% | 6.8% | 8.6% | -0.22% | 0.51% |
| Net Income | 15% | 31% | 20% | -1.1% | 1.7% |
| Stockholders Equity | 4.7% | 5% | 6.3% | 10% | 2% |
| FCF | 12% | 10% | 22% | 44% | 1.2% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +6.82%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +0.51%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +31.45%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is +1.73%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +5.04%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is +1.96%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +10.13%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is +1.24%.